TY - JOUR
T1 - 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults
AU - Creager, Mark A.
AU - Barnes, Geoffrey D.
AU - Giri, Jay
AU - Mukherjee, Debabrata
AU - Jones, William Schuyler
AU - Burnett, Allison E.
AU - Carman, Teresa
AU - Casanegra, Ana I.
AU - Castellucci, Lana A.
AU - Clark, Sherrell M.
AU - Cushman, Mary
AU - de Wit, Kerstin
AU - Eaves, Jennifer M.
AU - Fang, Margaret C.
AU - Goldberg, Joshua B.
AU - Henkin, Stanislav
AU - Johnston-Cox, Hillary
AU - Kadavath, Sabeeda
AU - Kadian-Dodov, Daniella
AU - Keeling, William Brent
AU - Klein, Andrew J.P.
AU - Li, Jun
AU - McDaniel, Michael C.
AU - Moores, Lisa K.
AU - Piazza, Gregory
AU - Prenger, Karen S.
AU - Pugliese, Steven C.
AU - Ranade, Mona
AU - Rosovsky, Rachel P.
AU - Russo, Farla
AU - Secemsky, Eric A.
AU - Sista, Akhilesh K.
AU - Tefera, Leben
AU - Weinberg, Ido
AU - Westafer, Lauren M.
AU - Young, Michael N.
N1 - Publisher Copyright:
© 2026 by the American College of Cardiology Foundation
PY - 2026/4/7
Y1 - 2026/4/7
N2 - AbstractAimThe “2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults” is a de novo guideline that provides comprehensive recommendations for the evaluation, management, and follow-up of adult patients (≥18 years of age) with acute pulmonary embolism (acute PE). A key feature of this guideline is the introduction of the AHA/ACC Acute Pulmonary Embolism Clinical Categories, which enhance the precision of severity classification, prognosis assessment, and evidence-based therapeutic decision-making.MethodsA comprehensive literature search was conducted from February 2024 to October 2024 to identify clinical studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Select key studies published until April 2025 were added by the guideline writing committee as appropriate.StructureThe focus of this clinical practice guideline is an evidence-based and patient-centered approach for acute PE evaluation and management of the adult patient. This guideline encompasses the period from the onset of symptoms through clinical follow-up, focusing on risk outcomes assessment, clinical diagnosis of acute PE, appropriate use of adjunctive cardiovascular testing, and management in both the acute and early post-acute phases of PE. It addresses evidence-based diagnostic and management strategies (including pharmacological therapies, advanced interventional therapies, and in-hospital support) for acute PE and associated outcomes.
AB - AbstractAimThe “2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults” is a de novo guideline that provides comprehensive recommendations for the evaluation, management, and follow-up of adult patients (≥18 years of age) with acute pulmonary embolism (acute PE). A key feature of this guideline is the introduction of the AHA/ACC Acute Pulmonary Embolism Clinical Categories, which enhance the precision of severity classification, prognosis assessment, and evidence-based therapeutic decision-making.MethodsA comprehensive literature search was conducted from February 2024 to October 2024 to identify clinical studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Select key studies published until April 2025 were added by the guideline writing committee as appropriate.StructureThe focus of this clinical practice guideline is an evidence-based and patient-centered approach for acute PE evaluation and management of the adult patient. This guideline encompasses the period from the onset of symptoms through clinical follow-up, focusing on risk outcomes assessment, clinical diagnosis of acute PE, appropriate use of adjunctive cardiovascular testing, and management in both the acute and early post-acute phases of PE. It addresses evidence-based diagnostic and management strategies (including pharmacological therapies, advanced interventional therapies, and in-hospital support) for acute PE and associated outcomes.
KW - AHA/ACC clinical practice guideline
KW - acute disease
KW - acute pulmonary embolism
KW - and venous thromboembolism
KW - anticoagulant
KW - chronic thromboembolic pulmonary hypertension
KW - diagnosis
KW - diagnostic imaging
KW - direct acting oral anticoagulant
KW - heparin
KW - hypertension, pulmonary
KW - imaging
KW - kidney disease
KW - kidney insufficiency
KW - multimodal imaging
KW - oral anticoagulants
KW - perfusion imaging
KW - pulmonary embolism
KW - risk assessment
KW - risk factors
KW - risk stratification
KW - thrombectomy
KW - thromboembolism
KW - thrombolytic therapy
KW - tomography
UR - https://www.scopus.com/pages/publications/105034570262
U2 - 10.1016/j.jacc.2025.11.005
DO - 10.1016/j.jacc.2025.11.005
M3 - Article
C2 - 41712898
AN - SCOPUS:105034570262
SN - 0735-1097
VL - 87
SP - 1626
EP - 1710
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 13
ER -